Literature DB >> 10729605

IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization.

R Zurbriggen1, I Novak-Hofer, A Seelig, R Glück.   

Abstract

Immunopotentiating reconstituted influenza virosomes (IRIV) are 150-nm proteoliposomes composed of influenza surface glycoproteins and a mixture of natural and synthetic phospholipids. Due to size, structure and composition of the IRIVs, they serve as an antigen carrier system for efficacious vaccination, as was demonstrated for hepatitis A and influenza. This paper reviews the unique properties of IRIVs and describes the in vivo biodistribution of model antigens using 14C-labeled IRIVs and 125I-labeled streptavidin. IRIV formulated streptavidin induced a strong depot effect after intra muscular (i.m.) vaccination of mice, whereas soluble streptavidin was soon eliminated via the kidney of the animals. A mixture of antigen and IRIVs yielded higher antibody titers after i.m. inoculation than streptavidin alone. The highest immunostimulation was achieved by the binding of the antigen to the investigated adjuvant. The potential penetration of inactivated hepatitis A virions into lipid membranes was assessed by measuring the area increase of a lipid monolayer kept at a constant surface pressure corresponding to that of lipid bilayer vesicles. The monolayers were composed of phosphatidylcholine (POPC) and phosphatidylethanolamine (POPE) (75/25 mol/mol), thus resembling the lipid composition of the IRIV. The results suggested that the hepatitis A antigen may spontaneously bind to the reconstituted IRIV membranes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729605     DOI: 10.1016/s0163-7827(99)00017-x

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  4 in total

1.  Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

Authors:  Rinaldo Zurbriggen; Mario Amacker; Andreas R Kammer; Nicole Westerfeld; Peter Borghgraef; Fred Van Leuven; Ingrid Van der Auwera; Stefaan Wera
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 2.  Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.

Authors:  Nicole Westerfeld; Gerd Pluschke; Rinaldo Zurbriggen
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

Review 3.  Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Authors:  Emily M Plummer; Marianne Manchester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010-09-24

Review 4.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.